These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37396067)

  • 1. The Efficacy and Influencing Factors of Polymyxin B in High-Level Carbapenem-Resistant
    Jia X; Yin Z; Zhang W; Du S
    Infect Drug Resist; 2023; 16():4177-4187. PubMed ID: 37396067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effect of Polymyxin B and Tigecycline to overcome Heteroresistance in Carbapenem-Resistant Klebsiella pneumoniae.
    Tian Y; Zhang Q; Wen L; Chen J
    Microbiol Spectr; 2021 Oct; 9(2):e0015221. PubMed ID: 34704782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study.
    Zhuang HH; Qu Q; Long WM; Hu Q; Wu XL; Chen Y; Wan Q; Xu TT; Luo Y; Yuan HY; Lu Q; Qu J
    Infection; 2024 Jun; ():. PubMed ID: 38884857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections.
    Lu Q; Zhu HH; Li GH; Qi TT; Ye LJ; Teng XQ; Qu Q; He GF; Qu J
    Front Med (Lausanne); 2021; 8():620885. PubMed ID: 33634151
    [No Abstract]   [Full Text] [Related]  

  • 5. Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study.
    Zheng G; Cai J; Zhang L; Chen D; Wang L; Qiu Y; Deng H; Bai H; Bian X; He J
    Infect Dis Ther; 2022 Oct; 11(5):1917-1934. PubMed ID: 35976531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections.
    Dubrovskaya Y; Chen TY; Scipione MR; Esaian D; Phillips MS; Papadopoulos J; Mehta SA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5394-7. PubMed ID: 23959321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The efficacy and safety of different antimicrobial regimens in carbapenem-resistant
    Sun WM; Zhou H; Shen LS; Yang Q; Ma WJ; Zhou JY
    Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):566-571. PubMed ID: 31365977
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.
    Satlin MJ; Kubin CJ; Blumenthal JS; Cohen AB; Furuya EY; Wilson SJ; Jenkins SG; Calfee DP
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5893-9. PubMed ID: 21968368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the Clinical Effect of Combined Drug Susceptibility to Guide Medication for Carbapenem-Resistant
    Yao H; Liu J; Jiang X; Chen F; Lu X; Zhang J
    Infect Drug Resist; 2021; 14():79-87. PubMed ID: 33469322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of in vitro efficacy of meropenem/polymyxin B and meropenem/fosfomycin combinations against carbapenem resistant Klebsiella pneumoniae strains.
    Adaleti R; Nakipoğlu Y; Çalık Ş; Arıcı N; Kansak N; Şenbayrak S; Aksaray S
    Acta Microbiol Immunol Hung; 2023 Jun; 70(2):155-160. PubMed ID: 37133999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant
    Fang J; Li H; Zhang M; Shi G; Liu M; Wang Y; Bian X
    Front Pharmacol; 2021; 12():780940. PubMed ID: 34955849
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of Donor-derived Carbapenem-resistant Klebsiella pneumoniae Infection after Renal Transplantation with Tigecycline and Extended-infusion Meropenem.
    Wang ZQ; Guo ZL; Feng H; Fu C; Zhao GY; Ma K; Zhu L; Chen G
    Curr Med Sci; 2021 Aug; 41(4):770-776. PubMed ID: 34403102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity.
    Rodrigues D; Baldissera GS; Mathos D; Sartori A; Zavascki AP; Rigatto MH
    Braz J Microbiol; 2021 Dec; 52(4):1913-1919. PubMed ID: 34191252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China.
    Li Y; Li J; Hu T; Hu J; Song N; Zhang Y; Chen Y
    Antimicrob Resist Infect Control; 2020 Jun; 9(1):79. PubMed ID: 32487221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.
    Su CF; Chuang C; Lin YT; Chan YJ; Lin JC; Lu PL; Huang CT; Wang JT; Chuang YC; Siu LK; Fung CP
    Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):651-659. PubMed ID: 29238934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant
    Kong W; Yang X; Shu Y; Li S; Song B; Yang K
    Front Public Health; 2023; 11():1118307. PubMed ID: 36926178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae.
    Zhao X; Li S; Zhang Y; Wang J; Wang C; Qin X; Hu F; Wang M
    Int J Antimicrob Agents; 2023 May; 61(5):106777. PubMed ID: 36905946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insertion sequence mediating mrgB disruption is the major mechanism of polymyxin resistance in carbapenem-resistant Klebsiella pneumoniae isolates from China.
    Chen X; Li P; Sun Z; Xu X; Jiang J; Su J
    J Glob Antimicrob Resist; 2022 Sep; 30():357-362. PubMed ID: 35817263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of carbapenem-resistant Klebsiella pneumoniae ST15 of producing KPC-2, SHV-106 and CTX-M-15 in Anhui, China.
    Zhao H; He Z; Li Y; Sun B
    BMC Microbiol; 2022 Nov; 22(1):262. PubMed ID: 36319965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections.
    Ny P; Nieberg P; Wong-Beringer A
    Am J Infect Control; 2015 Oct; 43(10):1076-80. PubMed ID: 26190386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.